SCHEMBL13675180

SCHEMBL13675180

Cc1ccc(S(=O)(=O)Nc2cccc3cc(C=O)[nH]c23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
LMNA P02545 4/20 0.50
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MAPT P10636 2/20 0.50
MITF O75030 1/20 0.50
S1PR4 O95977 1/20 0.50
S1PR1 P21453 1/20 0.50
AGTR1 P30556 1/20 0.50
OPRK1 P41145 1/20 0.50
HTT P42858 1/20 0.50
CKS1B P61024 1/20 0.50
SKP2 Q13309 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SLC40A1 Q9NP59 1/20 0.50
TUBB4A P04350 1/20 0.50
TUBB P07437 1/20 0.50
TUBA3C P0DPH7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1654047 0.79 TUBB4A (0.52) CYP2C9CYP2C19LMNAALDH1A1KMT2A
SCHEMBL1654857 0.78 TUBB4A (0.48) CYP2C9CYP2C19LMNAALDH1A1KMT2A
SCHEMBL2668598 0.77 SLC40A1 (0.55) ALDH1A1KMT2AMAPTSLC40A1TUBB4A
SCHEMBL1653280 0.77 NFKBIA (0.51) LMNAALDH1A1TDP1OPRK1HTT
SCHEMBL2367682 0.75 NR3C1 (0.64) CYP2C9CYP2C19LMNAALDH1A1KMT2A
SCHEMBL2668792 0.75 SLC40A1 (0.55) CYP2C9ALDH1A1KMT2ASLC40A1MEN1
SCHEMBL1653146 0.75 LMNA (0.60) CYP2C9LMNAALDH1A1KMT2ATDP1
SCHEMBL1653499 0.74 NSD2 (0.61) LMNAALDH1A1KMT2AMAPTHTT
SCHEMBL10993205 0.73 LMNA (0.65) CYP2C9CYP2C19LMNAALDH1A1KMT2A
SCHEMBL30958861 0.72 CYP2C9 (0.69) CYP2C9CYP2C19LMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247746-A1 Fused heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247746-A1 Fused heterocyclic compound GCKR, GCK, GPR119 CYP2C9 565/4885CYP2C19 346/4885LMNA 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.